Study links GLP-1 drugs such as semaglutide and tirzepatide to higher hair loss odds

Researchers reported that adults prescribed GLP-1 receptor agonists had higher odds of being diagnosed with two common types of hair loss within a year than matched adults who were not taking the drugs. The findings were published Feb. 9, 2026, in JAAD International ^[1].

The study used the TriNetX US Collaborative Network, which holds de-identified electronic health record data from 67 U.S. health care organizations, and covered 2014 through 2024 ^[1]. It compared 547,993 matched adult GLP-1 users and controls. Patients counted as GLP-1 users had at least two prescriptions for a drug in the class. Controls had at least two general medical encounters and no GLP-1 exposure. People with confounding skin, endocrine, nutritional or systemic conditions were excluded, and the groups were matched on age, sex, race, body mass index and type 2 diabetes status ^[1].

At six months, GLP-1 use was linked to higher odds of androgenetic alopecia (adjusted odds ratio 1.62) and of non-scarring hair loss overall (1.26), both with P values below .001. Telogen effluvium risk was higher in that window, but the result was not statistically significant (P = .18) ^[1].

At 12 months, the odds were higher for telogen effluvium (1.76), androgenetic alopecia (1.64) and non-scarring hair loss overall (1.40), all with P values below .001 ^[1]. An adjusted odds ratio compares the odds of a diagnosis in one group with the odds in the other; it is not a measure of how many people lost hair. The study did not report absolute risk, so how many users were affected is not known ^[1].

Alopecia areata ran the other way. It was consistently more common in the control group, which the authors read as evidence that GLP-1 receptor agonists do not significantly affect autoimmune hair loss ^[1].

Non-scarring hair loss is the broad category; telogen effluvium and androgenetic alopecia are subtypes. Rates of all three rose in both groups over the decade studied. The overall incidence curves began to diverge around 2019, with GLP-1 users consistently higher by 2023-2024, while telogen effluvium and androgenetic alopecia tracked similarly in both groups until 2021-2022 before rising more sharply among users ^[1].

The authors wrote that likely mechanisms include rapid weight loss, insulin and insulin-like growth factor 1 signaling, changes in androgens and direct effects on hair follicles ^[1]. They also noted that the slightly larger rise in androgenetic alopecia among users could reflect drug-related effects, metabolic effects or surveillance effects — that is, users being seen and diagnosed more often. The study is observational, so it cannot show that the drugs cause hair loss ^[1].

The analysis reported results for the GLP-1 receptor agonist class as a whole. It does not give separate numbers for semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound), though the authors cite earlier studies that linked alopecia to those two drugs ^[1].

Ten or fewer pediatric GLP-1 users experienced each hair loss outcome studied, which the authors said prevented meaningful comparisons in that age group ^[1]. The paper reports no outside funding and no conflicts of interest ^[1].

Why it matters for patients

Hair shedding is a visible side effect that can be distressing, and this study points to a consistent link between the drug class and the most common non-scarring types. Because the results are odds rather than counts, a person cannot use these numbers to estimate their own chance of losing hair.

Two details are worth keeping straight: alopecia areata, an autoimmune form, was not higher in users, and hair loss diagnoses increased in both groups over the study period, not only among people taking GLP-1 drugs. Whether hair regrows after a drug is stopped, or how long shedding lasts, has not been reported.

The authors said awareness of alopecia risk matters for early detection, counseling and coordinated care across specialties ^[1]. What patients and clinicians do with that information is not addressed by the study, and it contains no guidance from regulators.

What happens next

The authors call for research into the mechanisms behind the association, prospective monitoring and pediatric outcomes ^[1]. No specific follow-up study, label change or regulatory review has been announced.